Empagliflozin clinical studies
Pro Research Analysisby 
Searched over 200M research papers
Empagliflozin Clinical Trials: Safety and Efficacy in Type 2 Diabetes
Large pooled analyses of phase I–III clinical trials show that empagliflozin is generally safe and well tolerated in patients with type 2 diabetes (T2DM). The rates of adverse events, including severe and serious events, were similar to placebo. Hypoglycemia risk was not increased except in those also taking sulfonylureas. Genital infections were more common with empagliflozin, but urinary tract infection rates were similar to placebo. Other risks, such as bone fractures, cancer, renal events, and diabetic ketoacidosis, were not increased. The overall benefit–risk profile is favorable for T2DM patients, including those with chronic kidney disease (CKD) Kohler2017Tuttle2022.
Empagliflozin in Heart Failure: Benefits Beyond Diabetes
Empagliflozin has demonstrated significant benefits in heart failure patients, even in those without diabetes. In non-diabetic patients with heart failure and reduced ejection fraction (HFrEF), empagliflozin improved left ventricular function, reduced heart size, and enhanced exercise capacity and quality of life compared to placebo . In patients hospitalized for acute heart failure, empagliflozin provided significant clinical benefit within 90 days, regardless of diabetes status or ejection fraction, and was well tolerated .
Cardiovascular Outcomes in Type 2 Diabetes and Atherosclerotic Disease
In patients with T2DM and atherosclerotic cardiovascular disease, empagliflozin reduced the risk of major adverse cardiovascular events, heart failure hospitalization, and all-cause hospital admissions. These benefits were observed for both first and recurrent events, indicating a reduction in the total burden of cardiovascular complications . In those with both T2DM, established cardiovascular disease, and CKD, empagliflozin reduced cardiovascular death, all-cause mortality, and heart failure hospitalizations, with consistent effects across kidney function levels .
Empagliflozin and Chronic Kidney Disease: Slowing Progression
The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of kidney disease progression or cardiovascular death in a broad range of CKD patients, with or without diabetes. Hospitalizations from any cause were also reduced, and the safety profile was similar to placebo . In patients with T2DM and moderate to severe CKD, empagliflozin did not increase the risk of serious adverse events, and may lower the risk of hyperkalemia and edema .
Effects on Non-Alcoholic Fatty Liver Disease (NAFLD)
Empagliflozin has shown promise in improving liver steatosis and fibrosis in patients with NAFLD, both with and without T2DM. In non-diabetic NAFLD patients, empagliflozin improved liver fibrosis and, in those with significant steatosis, reduced liver fat. Liver enzymes and fasting insulin also improved . In NAFLD patients with T2DM, empagliflozin led to greater reductions in liver fat and stiffness compared to placebo and pioglitazone, and also reduced body weight and visceral fat .
Empagliflozin and Brain Insulin Sensitivity
In people with prediabetes, empagliflozin improved hypothalamic insulin sensitivity, which may contribute to its beneficial effects on metabolism and body fat distribution. This suggests a potential new approach for reversing brain insulin resistance .
Conclusion
Empagliflozin has been extensively studied in diverse populations, including those with T2DM, heart failure, CKD, and NAFLD. Clinical trials consistently show that empagliflozin is safe and provides significant benefits for cardiovascular, kidney, and liver outcomes, as well as improvements in metabolic health. These effects extend beyond glucose lowering, supporting its use in a wide range of patients at risk for cardiorenal and metabolic complications.
Sources and full results
Most relevant research papers on this topic